Actimis Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Actimis Pharmaceuticals Inc. spun out from the research division of Bayer Healthcare AG with rights to five programs that represent a significant portion of the total Bayer small-molecule therapeutics portfolio for respiratory diseases. In the first quarter of 2006, the company hopes to move its first compound, a novel and potential breakthrough asthma treatment, into human trials.